Black sea cucumber (*Holothuria atra* Jaeger, 1833) rescues *Pseudomonas aeruginosa*-infected *Caenorhabditis elegans* via reduction of pathogen virulence factors and enhancement of host immunity

Wan-Ting Lee^a, Boon-Khai Tan^a, Su-Anne Eng^b, Gan Chee Yuen^c, Kit Lam Chan^d, Yee Kwang Sim^e Shaida Fariza Sulaiman^b and Alexander Chong Shu-Chien^{a,b,f,*}

^aMalaysian Institute of Pharmaceuticals and Nutraceuticals (IPHARM), National Institute of Biotechnology Malaysia, Ministry of Energy, Science, Technology, Environment and Climate Change, Bukit Gambir, Malaysia; deniselwt@hotmail.com; tanboonkhai@gmail.com

^bSchool of Biological Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia; anne_es2810@hotmail.com; shaida@usm.my

^cAnalytical Biochemistry Research Centre, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia; cygan@usm.my

^dSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia; klchan@usm.my

^eCenter for Marine and Coastal Studies, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia; mrsimyk@usm.my

^fCentre for Chemical Biology, Sains@USM, Blok B No. 10, Persiaran Bukit Jambul, 11900 Bayan Lepas, Penang, Malaysia

* Correspondence: alex@usm.my; Tel: +6046535501

Abstract:

A strategy to circumvent the problem of multidrug resistant pathogen is consumption of functional food rich in anti-infectives targeting bacterial virulence or host immunity. The black sea cucumber (*Holothuria atra*) is a tropical marine sea cucumber species traditionally consumed as remedy for many ailments. There is a paucity of knowledge the anti-infectives capacity of *H. atra* and the underlying mechanisms involved. The objectives of this study were to utilize the *Caenorhabditis elegans*-*P. aeruginosa* infection model to assess the anti-infective properties of *H. atra*. We first showed the capacity of a *H. atra* extract and fraction in promoting survival of *C. elegans* during a customarily lethal *P. aeruginosa* infection. The same chemical entities also attenuate the production of several *P. aeruginosa* virulence factors and biofilm. Treatment of infected transgenic *lys-7::GFP* worms with *H. atra* fraction restored the repressed expression of *lys-7*, a defense enzyme, indicating improved host immunity. QTOF-LCMS analysis revealed the presence of aspidospermatidine, an indole alkaloid and inosine. Collectively, our finding shows that *H. atra* confers survival advantage in *C. elegans* against *P. aeruginosa* infection through inhibition of pathogen virulence and eventually, the restitution of host *lys-7* expression.

Keywords: *Pseudomonas aeruginosa*; *Caenorhabditis elegans*; *Holothuria atra*; anti-virulence; immunomodulator

29

30

1 1. Introduction

2 Increasing number of antibiotic resistance *P. aeruginosa*, an opportunistic pathogen
3 are being reported globally.¹ Attempts to overcome bacteria resistance through modification
4 of existing drugs or drug discovery are often ineffectual.² Collectively, these issues
5 underscore the need for alternative therapies with different modes of targeting mechanism
6 involving host immune response or pathogen virulence. In comparison to direct killing of
7 pathogens, these paths are projected to invoke milder evolutionary pressure responsible for
8 resistance development. Since nutrient status is a crucial contributing factor to immune
9 fitness, functional food with immunomodulator characteristic may play a pivotal role in
10 alleviation of infection.³

11 From the estimated 1000 varieties of sea cucumbers worldwide, around 20 species are
12 valued as functional food.⁴ Sea cucumbers are reported to be effective remedy for asthma,
13 hypertension, joint pain, sprains intestinal and urinary problems.^{5, 6} Correspondingly,
14 studies on sea cucumber metabolites have reported multiple activities including anticancer,
15 anticoagulant, anti-hypertension, anti-inflammatory, antimicrobial, antioxidant,
16 antithrombotic, antihyperglycemic, anti-ageing and wound healing.^{4, 7, 8} These bioactivities
17 are linked to a wide range of metabolites, such as triterpene glycosides, peptides, collagen,
18 mucopolysaccharides, carotenoids, polyunsaturated fatty acids and phospholipids.⁸⁻¹⁰
19 Therefore, sea cucumber is an opportune strategy to discover novel and potent
20 anti-infective entities. *Holothuria atra* Jaeger 1833 (Holothuridae), colloquially known as
21 black sea cucumber or lollyfish, is one of the most commonly found sea cucumber species in
22 the Indo-Pacific region, dwelling in seagrass beds and rocky reefs.¹¹ Among the many
23 medicinal properties linked with sea cucumbers, sea cucumbers are also traditionally
24 consumed for its immune boosting properties.⁵ In tandem, metabolites with *in vitro* or *in*
25 *vivo* immunomodulatory activities have been isolated from several sea cucumber species,
26 making this taxonomy group an opportune organism for discovery of novel and potent
27 anti-infective entities.¹²⁻¹⁵

28 The nematode *Caenorhabditis elegans* is a proven model for deciphering host–pathogen
29 interactions due to its readiness for infection by numerous human pathogens.¹⁶ As a model
30 organism, it is also supported by an array of tools useful for deciphering immunity related

31 pathways.¹⁷ The *C. elegans* host-pathogen interaction is a proven powerful platform for
32 discovery of anti-infectives and is frequently utilized to screen for novel anti-infectives
33 against a myriad of pathogens.^{18, 19} An advantage in having both host and pathogen in a
34 screening assay is early detection of undesirable toxic properties in hit candidates.²⁰ In
35 relation to food, *C. elegans* has been used as platform for deciphering various beneficial
36 properties of food including longevity, tolerance, lipid metabolism and stress resistance.²¹⁻²³

37 To date, the only published report of an anti-infective from marine invertebrates using
38 the *C. elegans* platform is from a tropical mollusk.²⁴ Using the *C. elegans* host-pathogen
39 platform, we investigated the anti-infective properties of *H. atra*. Overall, we demonstrate
40 the capacity of an extract from this sea cucumber in rescuing worms from a lethal *P.*
41 *aeruginosa* infection. The capacity of *H. atra* metabolites in impeding the production of
42 well-characterized *P. aeruginosa* virulence factors and boosting an immune-related gene
43 were also studied.

44

45 2. Results

46 2.1 *H. atra* promotes survival of *P. aeruginosa* PA14-infected *C. elegans* without direct 47 bactericidal effect

48 The slow-killing assay showed methanol extract of *H. atra* causing a significantly higher
49 percentage of worm survival ($60.21 \pm 6.7\%$) at 48 hours after treatment, which is comparable
50 to value obtained with curcumin ($60.68 \pm 8.6\%$), a known anti-infective against PA14
51 infection (Fig. 1). A lower percentage of survival ($56 \pm 7.6\%$) was obtained with the
52 acetone extract. The bactericidal effect of the methanol extract on *P. aeruginosa* PA14 was
53 determined. Extract concentrations ranging from 25 $\mu\text{g/mL}$ to 1000 $\mu\text{g/mL}$ did not reduce *P.*
54 *aeruginosa* PA14 growth, as compared to streptomycin at 100 $\mu\text{g/mL}$ (Supplementary 1).
55 This extract was also non-detrimental towards the growth kinetic of *P. aeruginosa* PA14, as
56 no significant difference was observed between *H. atra* and DMSO exposed bacteria
57 population (Fig. 2).

58 The lethality of *P. aeruginosa* PA14 infection in the slow killing assay involves the
59 colonization of *C. elegans* intestinal tract.²⁵ Therefore, we ascertain if the improved
60 survival of worms treated with extract is an outcome of reduced worm feeding activities.
61 We observed the worm pharyngeal pumping rate, a reliable indicator of bacterial feeding in

62 this species.²⁴ Results show no significant difference in feeding activities between
63 untreated worms fed PA14 with those treated with either 0.5% DMSO or methanol *H. atra*
64 extract, respectively (Fig. 3). Therefore, worms exposed to *H. atra* methanol extract still
65 display normal feeding activities, which presumably leads to gut colonization by the
66 ingested PA14 bacteria.

67 Column chromatography fractionation of the *H. atra* butanol partition resulted in 9
68 fractions (F1-F9). Based on the slow-killing assay, fractions F2 ($55.37 \pm 8.4\%$), F3 ($64.05 \pm$
69 8.8%), F4 ($52.75 \pm 6.3\%$) and F9 ($52.00 \pm 8.0\%$) resulted in significantly higher worm
70 survival as compared to 0.5% DMSO treatment (Fig. 4A). Dose dependent assay for fraction
71 F3 showed that 200 $\mu\text{g/mL}$ was the minimal concentration resulting in significantly highest
72 percentage of worm survival, comparable to value obtained with curcumin (Fig. 4B). At
73 higher concentrations, a decreasing trend of survival rates was observed. Fraction F3 also
74 did not appear to perturb *P. aeruginosa* PA14 growth (Fig. 4C).

75 **2.2 *H. atra* fraction inhibits the production of *P. aeruginosa* PA14 elastase, protease,**

76 **pyocyanin and formation of biofilm**

77 In comparison with 0.5% DMSO, treatment of *P. aeruginosa* PA14 with F3 significantly
78 suppressed the production of elastase and protease at 24 hr after treatment (Fig. 5A).
79 Formation of biofilm in microtiter plate was also attenuated with F3. As for pyocyanin,
80 significant reduction in pyocyanin production was obtained at 6 and 12 hr after incubation,
81 respectively, but not 24 hr. (Fig. 5B).

83 **2.3 *H. atra* induces the expression of *C. elegans* immune effector *lys-7* in PA14-infected**

84 **worms**

85 At 12 hr after infection, GFP intensity of *P. aeruginosa* PA14 infected worms was lower
86 than uninfected worms, indicating diminished *lys-7* expression (Fig. 6A). Treatment with
87 *H. atra* restored *lys-7* expression to a level comparable with uninfected worms.
88 Correspondingly, qPCR analysis of *lys-7* in worms also showed higher expression levels in
89 worms exposed to F3 at 12 or 24 hours after treatment (Fig. 6B). *H. atra* fraction also
90 resulted in higher *lys-7* expression as compared to curcumin.

91 **3.3 Tentative identification of major compounds in *H. atra* F3 and F4 fractions**

QTOF-LCMS separation detected two major peaks in F3 at Retention Times (R_T) 17.764 min and 18.395. The compounds were identified using an HR MS (accurate mass in negative mode) and HR MS/MS spectra (fragmentation) that matched with METLIN, MassBank and Chemspider databases. From the accurate mass analysis (Table 1), the molecular formula was calculated as $C_{18}H_{22}N_2$ and $C_{10}H_{12}N_4O_5$, respectively. The compounds were putatively identified as aspidospermatidine and inosine.

3. Experimental

3.1 Bacterial and Nematode Strains

P. aeruginosa strain PA14²⁶, which is rifampicin-resistant, was grown in King's B broth supplemented with rifampicin (100 μ g/mL) while the streptomycin-resistant *E. coli* strain OP50²⁷ was cultured in Luria Bertani (LB) broth with streptomycin (100 μ g/mL). Cultures were grown overnight with aeration at 37°C. The wild type *C. elegans* Bristol N2 (N2) and transgenic *lys-7::GFP* worm strain SAL105 were obtained from the *Caenorhabditis* Genetics Center (CGC), USA, with growth and handling as described elsewhere.²⁷ Standard Operating Procedures involving *C. elegans* and living modified organisms (LMOs) were approved by the Universiti Sains Malaysia Animal Ethic Committee (AECUSM) and the Institutional Biosafety Committee (UKKP)

3.2 Preparation of *H. atra* extract

Holothuria atra was collected from Pulau Songsong Kedah situated at the northern region of Peninsular Malaysia (N5°48'33.72" E100°17'32.63") and authenticated by the Centre for Marine and Coastal Studies, Universiti Sains Malaysia. Samples were stored at -20°C until further processing. Frozen samples were cleaned with distilled water, sliced into smaller pieces and freeze-dried for about 5-7 days. Dried samples were extracted with either methanol or acetone, followed by 15 minutes of sonication at room temperature and lastly, filtration with Whatman filter paper No. 1. Extraction procedure was repeated thrice. Filtrates were then concentrated using a rotary evaporator at 39°C. All dried extracts were kept at -20°C before dilution in DMSO at 20mg/mL, followed by storage at 4°C. Depending on assays, the extract stock solution is further diluted to achieve the desired concentrations.

3.3 *C. elegans* survival Assay

122 The slow killing assay was performed according to the protocol described elsewhere.²⁸
 123 PA14 cultured overnight on King's B broth was evenly spread on Pseudomonas Infection
 124 Agar (PIA) assay plates supplemented with natural products, followed by incubation at 37°C
 125 for 24 hours to allow growth of PA14. Triplicate plates containing 50-60 young adult worms
 126 each were used. At least three independent repeats were performed.

127 Percentage survival of the infected worm population was determined after 48 hours of
 128 incubation at 25°C. DMSO (0.5%) and curcumin (100 µg/mL), a known anti-infective agent,
 129 was used as negative and positive control, respectively.²⁹

130 **3.4 Antimicrobial test**

131 The minimum inhibitory concentration (MIC) broth microdilution antimicrobial test was
 132 carried out to determine bactericidal activities of natural product. Stock solution of extracts
 133 or fractions were further diluted in DMSO to achieve concentration ranging from 25 µg/mL
 134 to 1000 µg/mL. Overnight culture of *P. aeruginosa* PA14 was adjusted to 0.5 McFarland
 135 standard turbidity and diluted to 1:20. A total of 10 µL of inoculum was added into the wells,
 136 followed by incubation at 37°C for 24 hours. Streptomycin (100 µg/mL) and DMSO (0.5%)
 137 were also tested as positive and negative controls, respectively.

138 **3.5 Bacterial growth assay**

139 The assay was conducted with similar preparations as the MIC broth microdilution test.
 140 Upon inoculum addition, the well plate was incubated at 37°C with aeration and bacterial cell
 141 density was measured at OD₆₀₀ every 2 hours.

142 **3.6 Liquid-liquid partitioning of methanolic *H. atra* extract**

143 The methanol extract was subjected to liquid-liquid chromatography, to separate
 144 compounds according to polarity. The extract was suspended in distilled water and
 145 subsequently partitioned with butanol. The partition was collected and dried with a rotatory
 146 evaporator, followed by storage at -20°C. Stock solution for the partition was prepared in
 147 DMSO and stored at 4°C.

148 **3.7 Fractionation of *H. atra* butanol partition**

149 The butanol partition was column chromatographed over silica gel 60 (70-230 mesh) and
 150 eluted stepwise from 100:0:1 to 0:100:1 with the chloroform:methanol:water solvent system
 151 at ratio of 80:20:1. The process was repeated until sufficient fractions were obtained.

152 3.8 Virulence factors and biofilm production assays

153 Protease and elastase activity assays were performed as described elsewhere, with minor
154 modifications.³⁰ Briefly, *P. aeruginosa* PA14 was grown in the presence of bioactive
155 fraction at 200 µg/mL or DMSO (0.5%) for 24 hours at 37°C. The supernatants were
156 collected and filtered with a 0.22 µm nylon filter. Reaction mixture consisting of 0.8%
157 azocasein in 500 µL of 50mM K₂HPO₄ (pH7) and 100 µL of the purified supernatant were
158 incubated at 25°C for 3 hours. A total of 0.5 mL of 1.5M HCl was added into the reaction,
159 followed by placement on ice for 30 minutes and centrifugation. After the addition of 0.5 mL
160 1M NaOH, the absorbance was measured at 400nm (SpectraMax M5).

161 As for elastase activity, 100 µL of the purified supernatant described above was added
162 into tubes pre-prepared with 1 mL of 10mM Na₂HPO₄ and 20 mg of elastin-Congo red. The
163 mixtures were then incubated at 37°C for 4 hours with agitation. After the incubation, the
164 mixtures were centrifuged at 14 000 rpm for 10 minutes and absorbance determined at
165 495nm.

166 The pyocyanin quantification assay was conducted as described.³¹ *P. aeruginosa* PA14
167 was grown in the presence of bioactive fraction for up to 24 hours at 37°C. Cultures were
168 collected at 6, 12 and 24 hours after treatments and centrifuged. A total of 3 mL chloroform
169 was then added into the resulting supernatant, vortexed briefly and centrifuged for 10
170 minutes at 10 000 rpm. The bottom blue layer was isolated, and the extraction processes were
171 repeated using 1.5 mL of 1M HCl. The absorbance at 520 nm of the pink layer was measured.
172 Pyocyanin concentration was determined by multiplying the absorbance value with 17.072.

173 A microtiter biofilm formation assay was used to determine the effect of *H. atra* fraction
174 on *P. aeruginosa* PA14 biofilm formation.³² *P. aeruginosa* PA14 was grown overnight
175 followed by dilution to 1:100. A total of 100 µL of the inoculum was added into 96 wells
176 plate preseeded with *H. atra* fraction or 0.5% DMSO. The plate was then incubated for 24
177 hours at 37°C. Liquid and cells were discarded, followed by rinsing of plate with distilled
178 water. For visualisation, 125 µL of 0.1% crystal violet solution was added into each well,
179 followed by incubation for 15 minutes at room temperature. Excessive stain was washed off
180 with water and wells left air-dried for 2 hours. Stained biofilm was treated with 125 µL of
181 30% acetic acid followed by 10-15 min incubation. A total of 125 µL of solubilized crystal
182 violet was transferred into a new microtiter for measurement at 550 nm.

183 3.9 Visualization of transgenic *lys-7::GFP C. elegans*

Transgenic *C. elegans* *lys-7::GFP* strain SAL105 were exposed *P. aeruginosa* PA14 in the presence or absence of *H. atra* fractions as described in the slow killing assay. The fluorescence intensities of young adult worms at 12 hpi for all the experimental conditions were visualized using Leica Microsystem M205 FA microscope and digitally captured with Leica DFC310 FX camera (60x magnification)

3.10 Real-time PCR based quantification of *lys-7* expression in *C. elegans*

Primers were designed accordingly for the amplification of *C. elegans* *lys-7* and pan-actin as housekeeping gene. Total RNA was treated with RNase-free DNase (Promega, USA) for removal of genomic DNA. PCR optimization and amplification was performed under condition described previously.²⁸ Melt curve analysis was performed to ensure the specificity of the PCR products. Quantitative expression of *lys-7* was calculated using CFX Manager software (BioRad, USA) by normalizing its level to housekeeping gene. Three independent replicates were performed for each analysis.

3.11 Chemical profiling of fractions

Compounds identification of both the *H. atra* active fractions were performed using the Agilent 6520 accurate-mass quadrupole time-of-flight liquid chromatography mass spectroscopy (QTOF-LCMS). Zorbax SB-C18 column (1.5µm particle size, 0.5x150mm) was used and separation was achieved with a 22.5 minutes gradient of 3-90% acetonitrile, followed by 3% acetonitrile for 10 minutes at a flow rate of 20 µL/min. Solvents contained 0.1% formic acid. The compound prediction was achieved by comparing the obtained individual MS/MS fingerprinting spectrum with METLIN, MassBank and Chemspider databases.

3.12 Statistical analysis

Data were analyzed using Student's *t*-test whereby in all comparisons, $p < 0.05$, $p < 0.01$ and $p < 0.001$ were accepted as statistically significant.

4. Discussion

An ongoing strategy to overcome the problem of drug-resistant pathogens is discovery of anti-infective activity, which either disrupt virulence-related pathways or boost host immunity. The diverse marine environment imposes the selection of an array of metabolites produced by an immeasurable source of organisms. Marine natural products with anti-virulence or immunomodulatory properties have been reported.³³⁻³⁷. Among edible

marine organisms, sea cucumber is regarded as a potent source of novel entities useful for both nutraceutical and pharmaceutical industries. There is an increasing reports of bioactivities from *H. atra*, a widely distributed tropical sea cucumber species. This includes antibacterial, antifungal, anti-proliferative, anti-apoptotic and antioxidant properties.^{6, 38-43} We report here for the first time the anti-infective capacity of *H. atra* extract through an *in vivo*

Our results showed that the *H. atra* methanol extract conferred survival to *P. aeruginosa* PA14-infected *C. elegans* without possessing direct bactericidal activity towards *P. aeruginosa* PA14, ruling out bacteria mortality as reason for improved worm survival. Previously, a methanol extract of *H. atra* was also reported to not exert any bactericidal effect on several pathogenic bacteria species, including *P. aeruginosa*.⁴⁴ Further separation of the *H. atra* methanol extract yielded a fraction with similar bioactive properties. The range of worm survival obtained with this fraction is comparable to levels using a similar slow-killing assay where infected worms were treated with a terrestrial plant seed extract²⁸ or curcumin.²⁹ These levels however, are lower than a fraction isolated from a tropical marine actinomycete.⁴⁵

In order to better understand the mechanisms responsible for the survival of infected worms, we assessed the effect of *H. atra* towards several *P. aeruginosa* PA14 virulence factors. Although the complete spectrum of the pathogenesis of *C. elegans*-*P. aeruginosa* slow killing assay is not fully understood, the involvement of multiple virulence factors such as pyocanin, pyoverdine, various proteases, elastase, phospholipase and exotoxin is canonical.^{25, 26} Results show *H. atra* lowered both proteolytic and elastolytic activities, and diminished the production of pyocyanin and formation of biofilm, collectively signifying the attenuation of *P. aeruginosa* PA14 virulence. In addition, the collective mitigation of these virulence factors suggests a possible interference of PA14 quorum sensing (QS) by *H. atra* metabolites. QS have been corroborated as a crucial factor responsible for host mortality in the *C. elegans* slow killing assay. Elsewhere, a marine seaweed extract was reported to repress *P. aeruginosa* QS genes, leading to diminished production of virulence factors and survival of infected worms.³⁶ Future work should ascertain the capacities of *H. atra* metabolites in interfering with pivotal elements of the *P. aeruginosa* QS pathway.

The bioactive fraction was also able to restore the expression of *lys-7*, which encodes an immune-specific lysozyme which facilitates the clearance of bacterial infection through disruption of bacterial cell wall peptidoglycans.⁴⁶ Two plausible reasons could explain the

restitution of *lys-7*. A known characteristic of *P. aeruginosa* infection in *C. elegans* is the suppression of host *lys-7* through the subversion of the DAF-2/DAF-16 insulin-like signaling pathway, leading to the downstream transcriptional suppression of several antimicrobial factors, including *lys-7*.⁴⁶⁻⁴⁸ Since the *H. atra* F3 fraction could mutually reduce the production of virulence factors and restore expression of *lys-7* in infected worms, it is possible that the latter observation is a consequence of halting the *P. aeruginosa* virulence activities upstream of the DAF2-DAF16 pathway. This would mimic the effects exerted by a marine brown seaweed extract in overcoming the pathogenicity of PA14 towards *C. elegans*.³⁵ The second possible explanation is that *H. atra* also contain compounds capable of directly inducing *lys-7* activities.^{45, 49}

Compounds with immunomodulatory activities have been isolated from edible sea cucumber species such as *Cucumaria japonica*, *C. frondosa* and *Stichopus japonicus*.¹²⁻¹⁵ Among these anti-infective molecules, polysaccharides are the most studied group.^{15, 50} In addition, some triterpene glycosides, which are prominent secondary metabolites in sea cucumbers, also possessed immune-boosting effects.¹⁰ Two examples, cucumariosides and frondoside, were reported to promote cellular immunity through stimulation of phagocytosis and lysosomal activities.^{12, 14, 51} In this study, the main constituents detected in the bioactive *H. atra* fraction are aspidospermatidine and inosine. Aspidospermatidine is an indole alkaloid, a large and growing group of potentially useful marine-based metabolites.⁵² Elsewhere, alkaloids have been identified in *H. atra* extract.⁴² Indole and its derivatives have been demonstrated to repress the *P. aeruginosa* QS system, leading to diminished production of protease, pyocyanin and biofilm.⁵³⁻⁵⁵ Inosine, a deaminated product of adenosine, has also been highlighted elsewhere as having immunomodulatory and neuroprotective properties.⁵⁶⁻⁵⁸

5. Conclusions

Using *C. elegans* as host model organism, we propose that *H. atra* has anti-infective properties against *P. aeruginosa*. A bioactive fraction of this sea cucumber species inhibits the production of pathogen virulence factors. Concomitantly, *H. atra* also restored the expression level of host *lys-7*. Collectively, this signifies an *in vivo* anti-infective capacity in *H. atra* which maybe mitigate concerns related with drug resistant pathogens.

Acknowledgments: We thank Universiti Sains Malaysia for postdoctoral appointment for Su-Anne E. Wan-Ting L. was supported by the MyBrain15 Scholarship from the Ministry of Education, Malaysia. This work was supported by the Malaysia Ministry of Science, Technology and Innovation under the IPHARM Flagship Research Grant 'Development of Nutraceutical and Pharmaceutical Products for Therapeutic Indications of High Burden to Malaysia' [Grant Number 304/PBIOLOGI/650869/K105].

References

1. J. Yayan, B. Ghebremedhin and K. Rasche, Antibiotic Resistance of *Pseudomonas aeruginosa* in Pneumonia at a Single University Hospital Center in Germany over a 10-Year Period, *PLoS One*, 2015, **10**, e0139836.
2. A. Parisien, B. Allain, J. Zhang, R. Mandeville and C. Q. Lan, Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides, *J. Appl. Microbiol.*, 2008, **104**, 1-13.
3. P. C. Calder and S. Kew, The immune system: a target for functional foods?, *British Journal of Nutrition*, 2002, **88**, S165-S176.
4. S. Bordbar, F. Anwar and N. Saari, High-value components and bioactives from sea cucumbers for functional foods--a review, *Mar. Drugs*, 2011, **9**, 1761-1805.
5. J. Chen, Present status and prospects of sea cucumber industry in China, *Journal*, 2004, 25-38.
6. A. I. Dakrory, S. R. Fahmy, A. M. Soliman, A. S. Mohamed and S. A. M. Amer, Protective and Curative Effects of the Sea Cucumber *Holothuria atra* Extract against DMBA-Induced Hepatorenal Diseases in Rats, *Biomed Res. Int.*, 2015, **2015**, 11.
7. P. Jattujan, P. Chalorak, T. Siangcham, K. Sangpairoj, S. Nobsathian, T. Poomtong, P. Sobhon and K. Meemon, *Holothuria scabra* extracts possess anti-oxidant activity and promote stress resistance and lifespan extension in *Caenorhabditis elegans*, *Experimental Gerontology*, 2018, **110**, 158-171.
8. D. L. Aminin, E. S. Menchinskaya, E. A. Pislugin, A. S. Silchenko, S. A. Avilov and V. I. Kalinin, Anticancer activity of sea cucumber triterpene glycosides, *Mar. Drugs*, 2015, **13**, 1202-1223.
9. H. A. H. Ibrahim, Antibacterial carotenoids of three *Holothuria* species in Hurghada, Egypt, *Egypt J. Aquat. Res.*, 2012, **38**, 185-194.
10. Y. Bahrami and C. M. Franco, Acetylated Triterpene Glycosides and Their Biological Activity from Holothuroidea Reported in the Past Six Decades, *Mar. Drugs*, 2016, **14**.
11. C. Conand, in *Advances in sea cucumber aquaculture and management. Fisheries Technical Paper No. 463*, eds. L. A., C. C., P. S., U. S., H. J.-F. and M. A., FAO, Rome, 2004, pp. 13-24.
12. D. L. Aminin, I. G. Agafonova, V. I. Kalinin, A. S. Silchenko, S. A. Avilov, V. A. Stonik, P. D. Collin and C. Woodward, Immunomodulatory Properties of Frondoside A, a Major

- 319 Triterpene Glycoside from the North Atlantic Commercially Harvested Sea Cucumber
320 *Cucumaria frondosa*, *J. Med. Food*, 2008, **11**, 443-453.
- 321 13. D. L. Aminin, B. V. Pinegin, L. V. Pichugina, T. S. Zaporozhets, I. G. Agafonova, V. M.
322 Boguslavski, A. S. Silchenko, S. A. Avilov and V. A. Stonik, Immunomodulatory properties
323 of Cumaside, *Int. Immunopharmacol.*, 2006, **6**, 1070-1082.
- 324 14. D. Aminin, E. Pislyagin, M. Astashev, A. Es'kov, V. Kozhemyako, S. Avilov, E. Zelepuga,
325 E. Yurchenko, L. Kaluzhskiy, E. Kozlovskaya, A. Ivanov and V. Stonik, Glycosides from
326 edible sea cucumbers stimulate macrophages via purinergic receptors, *Sci. Rep.*, 2016, **6**,
327 39683.
- 328 15. Y. Song, S.-J. Jin, L.-H. Cui, X.-J. Ji and F.-G. Yang, Immunomodulatory Effect of *Stichopus*
329 *japonicus* Acid Mucopolysaccharide on Experimental Hepatocellular Carcinoma in Rats,
330 *Molecules*, 2013, **18**, 7179.
- 331 16. T. I. Moy, A. R. Ball, Z. Anklesaria, G. Casadei, K. Lewis and F. M. Ausubel, Identification
332 of novel antimicrobials using a live-animal infection model, *Proc. Natl. Acad. Sci. U.S.A.*,
333 2006, **103**, 10414-10419.
- 334 17. A. Aballay and F. M. Ausubel, *Caenorhabditis elegans* as a host for the study of
335 host-pathogen interactions, *Curr Opin Microbiol*, 2002, **5**, 97-101.
- 336 18. A. L. Conery, J. Larkins-Ford, F. M. Ausubel and N. V. Kirienko, High-Throughput
337 Screening for Novel Anti-Infectives Using a *C. elegans* Pathogenesis Model, *Curr.*
338 *Protocols Chem. Biol*, 2014, **6**, 25-37.
- 339 19. P. D. Utari and W. J. Quax, *Caenorhabditis elegans* reveals novel *Pseudomonas aeruginosa*
340 virulence mechanism, *Trends in Microbiology*, 2013, **21**, 315-316.
- 341 20. B. Squiban and C. L. Kurz, *C. elegans*: an all in one model for antimicrobial drug discovery,
342 *Curr. Drug Targets*, 2011, **12**, 967-977.
- 343 21. D. Navarro-Herrera, P. Aranaz, L. Eder-Azanza, M. Zabala, C. Hurtado, A. Romo-Hualde, J.
344 A. Martínez, C. J. González-Navarro and J. L. Vizmanos, Dihomo-gamma-linolenic acid
345 induces fat loss in *C. elegans* in an omega-3-independent manner by promoting peroxisomal
346 fatty acid β -oxidation, *Food & Function*, 2018, **9**, 1621-1637.
- 347 22. P. Yuan, L.-y. Pan, L.-g. Xiong, J.-w. Tong, J. Li, J.-a. Huang, Y.-s. Gong and Z.-h. Liu,
348 Black tea increases hypertonic stress resistance in *C. elegans*, *Food & Function*, 2018, **9**,
349 3798-3806.
- 350 23. Y. Zhou, Q. Xu, X. Zhou, S. Song and B. Zhu, Stress resistance and lifespan extension of
351 *Caenorhabditis elegans* enhanced by peptides from mussel (*Mytilus edulis*) protein
352 hydrolyzate, *Food & Function*, 2018, **9**, 3313-3320.
- 353 24. C. Kong, W. A. Yehye, N. Abd Rahman, M. W. Tan and S. Nathan, Discovery of potential
354 anti-infectives against *Staphylococcus aureus* using a *Caenorhabditis elegans* infection
355 model, *BMC Complement. Altern. Med.*, 2014, **14**, 4.
- 356 25. M. W. Tan, S. Mahajan-Miklos and F. M. Ausubel, Killing of *Caenorhabditis elegans* by
357 *Pseudomonas aeruginosa* used to model mammalian bacterial pathogenesis, *Proc. Natl.*
358 *Acad. Sci. U.S.A.*, 1999, **96**, 715-720.
- 359 26. L. G. Rahme, E. J. Stevens, S. F. Wolfort, J. Shao, R. G. Tompkins and F. M. Ausubel,
360 Common virulence factors for bacterial pathogenicity in plants and animals, *Science*, 1995,
361 **268**, 1899-1902.

- 362 27. S. Brenner, The genetics of *Caenorhabditis elegans*, *Genetics*, 1974, **77**, 71-94.
- 363 28. K. Dharmalingam, B.-K. Tan, M. Z. Mahmud, S. A. M. Sedek, M. I. A. Majid, M.-K. Kuah,
364 S. F. Sulaiman, K. L. Ooi, N. A. K. Khan, T. S. T. Muhammad, M.-W. Tan and A. C.
365 Shu-Chien, *Swietenia macrophylla* extract promotes the ability of *Caenorhabditis elegans* to
366 survive *Pseudomonas aeruginosa* infection, *J. Ethnopharmacol.*, 2012, **139**, 657-663.
- 367 29. T. Rudrappa and H. P. Bais, Curcumin, a known phenolic from *Curcuma longa*, attenuates
368 the virulence of *Pseudomonas aeruginosa* PAO1 in whole plant and animal pathogenicity
369 models, *J. Agric. Food Chem.*, 2008, **56**, 1955-1962.
- 370 30. B. Prithiviraj, H. P. Bais, T. Weir, B. Suresh, E. H. Najarro, B. V. Dayakar, H. P. Schweizer
371 and J. M. Vivanco, Down regulation of virulence factors of *Pseudomonas aeruginosa* by
372 salicylic acid attenuates its virulence on *Arabidopsis thaliana* and *Caenorhabditis elegans*,
373 *Infect. Immun.*, 2005, **73**, 5319-5328.
- 374 31. D. W. Essar, L. Eberly, A. Hadero and I. P. Crawford, Identification and characterization of
375 genes for a second anthranilate synthase in *Pseudomonas aeruginosa*: interchangeability of
376 the two anthranilate synthases and evolutionary implications, *J. Bacteriol.*, 1990, **172**,
377 884-900.
- 378 32. G. A. O' Toole, Microtiter dish biofilm formation assay, *J. Vis. Exp.*, 2011, DOI:
379 10.3791/2437, e2437.
- 380 33. D. N. Naik, S. Wahidullah and R. M. Meena, Attenuation of *Pseudomonas aeruginosa*
381 virulence by marine invertebrate-derived *Streptomyces* sp, *Lett. Appl. Microbiol.*, 2013, **56**,
382 197-207.
- 383 34. R. Papa, L. Selan, E. Parrilli, M. Tilotta, F. Sannino, G. Feller, M. L. Tutino and M. Artini,
384 Anti-Biofilm Activities from Marine Cold Adapted Bacteria Against *Staphylococci* and
385 *Pseudomonas aeruginosa*, *Front. Microbiol.*, 2015, **6**, 1333.
- 386 35. S. Kandasamy, W. Khan, F. Evans, A. T. Critchley and B. Prithiviraj, Tasco^(R): a product of
387 *Ascomyces nodosum* enhances immune response of *Caenorhabditis elegans* against
388 *Pseudomonas aeruginosa* infection, *Mar. Drugs*, 2012, **10**, 84-105.
- 389 36. G. Kulshreshtha, T. Borza, B. Rathgeber, G. S. Stratton, N. A. Thomas, A. Critchley, J.
390 Hafting and B. Prithiviraj, Red Seaweeds *Sarcodiotheca gaudichaudii* and *Chondrus crispus*
391 down Regulate Virulence Factors of *Salmonella* Enteritidis and Induce Immune Responses in
392 *Caenorhabditis elegans*, *Front. Microbiol.*, 2016, **7**, 421.
- 393 37. J. Liu, J. Hafting, A. T. Critchley, A. H. Banskota and B. Prithiviraj, Components of the
394 cultivated red seaweed *Chondrus crispus* enhance the immune response of *Caenorhabditis*
395 *elegans* to *Pseudomonas aeruginosa* through the pmk-1, daf-2/daf-16, and skn-1 pathways,
396 *Appl. Environ. Microb.*, 2013, **79**, 7343-7350.
- 397 38. B. H. Ridzwan, M. A. Kaswandi, Y. Azman and M. Fuad, Screening for antibacterial agents
398 in three species of sea cucumbers from coastal areas of Sabah, *Gen. Pharmacol.*, 1995, **26**,
399 1539-1543.
- 400 39. D. I. Dhinakaran and A. P. Lipton, Antitumor and antifungal activities of organic extracts of
401 sea cucumber *Holothuria atra* from the southeast coast of India, *J. Ocean U. China*, 2015, **14**,
402 185-189.

- 403 40. Y. Nishikawa, A. Furukawa, I. Shiga, Y. Muroi, T. Ishii, Y. Hongo, S. Takahashi, T.
404 Sugawara, H. Koshino and M. Ohnishi, Cytoprotective Effects of Lysophospholipids from
405 Sea Cucumber *Holothuria atra*, *PLOS ONE*, 2015, **10**, e0135701.
- 406 41. A. Y. Esmat, M. M. Said, A. A. Soliman, K. S. H. El-Masry and E. A. Badiea, Bioactive
407 compounds, antioxidant potential, and hepatoprotective activity of sea cucumber (*Holothuria*
408 *atra*) against thioacetamide intoxication in rats, *Nutrition*, 2013, **29**, 258-267.
- 409 42. D. I. Dhinakaran and A. P. Lipton, Bioactive compounds from *Holothuria atra* of Indian
410 ocean, *Springerplus*, 2014, **3**, 673.
- 411 43. D. Y. Saad, A. A. Baiomy and A. A. Mansour, Antiseptic effect of sea cucumber (*Holothuria*
412 *atra*) against multi-organ failure induced by sepsis: Molecular and histopathological study,
413 *Exp. Ther. Med.*, 2016, **12**, 222-230.
- 414 44. A. J. Lawrence, R. Afifi, M. Ahmed, S. Khalifa and T. Paget, Bioactivity as an Options Value
415 of Sea Cucumbers in the Egyptian Red Sea, *Conserv. Biol.*, 2010, **24**, 217-225.
- 416 45. S. N. Fatin, T. Boon-Khai, A. C. Shu-Chien, M. Khairuddean and A. Al-Ashraf Abdullah, A
417 Marine Actinomycete Rescues *Caenorhabditis elegans* from *Pseudomonas aeruginosa*
418 Infection through Restitution of Lysozyme 7, *Front. Microbiol.*, 2017, **8**, 2267.
- 419 46. E. A. Evans, T. Kawli and M. W. Tan, *Pseudomonas aeruginosa* suppresses host immunity
420 by activating the DAF-2 insulin-like signaling pathway in *Caenorhabditis elegans*, *PLoS*
421 *Pathog.*, 2008, **4**, e1000175.
- 422 47. D. A. Garsin, J. M. Villanueva, J. Begun, D. H. Kim, C. D. Sifri, S. B. Calderwood, G.
423 Ruvkun and F. M. Ausubel, Long-lived *C. elegans* daf-2 mutants are resistant to bacterial
424 pathogens, *Science*, 2003, **300**, 1921.
- 425 48. C. T. Murphy, S. A. McCarroll, C. I. Bargmann, A. Fraser, R. S. Kamath, J. Ahringer, H. Li
426 and C. Kenyon, Genes that act downstream of DAF-16 to influence the lifespan of
427 *Caenorhabditis elegans*, *Nature*, 2003, **424**, 277.
- 428 49. W. H. Li, C. H. Chang, C. W. Huang, C. C. Wei and V. H. Liao, Selenite enhances immune
429 response against *Pseudomonas aeruginosa* PA14 via SKN-1 in *Caenorhabditis elegans*,
430 *PLoS One*, 2014, **9**, e105810.
- 431 50. H. Wang, S. Yang, Y. Wang, T. Jiang, S. Li and Z. Lv, Immunoenhancement Effects of
432 Glycosaminoglycan from *Apostichopus japonicus*: In Vitro and In
433 Cyclophosphamide-Induced Immunosuppressed Mice Studies, *Mar. Drugs*, 2017, **15**, 347.
- 434 51. D. L. Aminin, I. G. Agafonova, E. V. Berdyshev, E. G. Isachenko, S. A. Avilov and V. A.
435 Stonik, Immunomodulatory Properties of Cucumariosides from the Edible Far-Eastern
436 Holothurian *Cucumaria japonica*, *J. Med. Food*, 2001, **4**, 127-135.
- 437 52. N. Netz and T. Opatz, Marine Indole Alkaloids, *Mar. Drugs*, 2015, **13**, 4814-4914.
- 438 53. J. Kim and W. Park, Indole inhibits bacterial quorum sensing signal transmission by
439 interfering with quorum sensing regulator folding, *Microbiology*, 2013, **159**, 2616-2625.
- 440 54. J. Lee, C. Attila, S. L. G. Cirillo, J. D. Cirillo and T. K. Wood, Indole and 7-hydroxyindole
441 diminish *Pseudomonas aeruginosa* virulence, *Microbiol. Biotechnol.*, 2009, **2**, 75-90.
- 442 55. J.-H. Lee, Y.-G. Kim, M. H. Cho, J.-A. Kim and J. Lee, 7-fluoroindole as an antivirulence
443 compound against *Pseudomonas aeruginosa*, *Fems Microbiol Lett*, 2012, **329**, 36-44.
- 444 56. X. Jin, R. K. Shepherd, B. R. Duling and J. Linden, Inosine binds to A3 adenosine receptors
445 and stimulates mast cell degranulation, *J. Clin. Invest.*, 1997, **100**, 2849-2857.

- 446 57. L. I. Benowitz, D. E. Goldberg and N. Irwin, in *Progress in Brain Research*, eds. L.
447 McKerracher, G. Doucet and S. Rossignol, Elsevier, 2002, vol. 137, pp. 389-399.
448 58. P. Chen, D. E. Goldberg, B. Kolb, M. Lanser and L. I. Benowitz, Inosine induces axonal
449 rewiring and improves behavioral outcome after stroke, *Proc. Natl. Acad. Sci. U.S.A.*, 2002,
450 **99**, 9031-9036.

451

452

453

454

455

456

457

458 **Table 1.** Aspidospermatidine and inosine, the main compounds identified in F3
459 fraction of *Holothuria atra*

ESI-MS RT (min)	Detected ion (<i>m/z</i>) [M-H] ⁻	Fragments	Molecular Formula	Identification
17.764	266.1789	266, 144, 136, 130	C ₁₈ H ₂₂ N ₂	Aspidospermatidine
18.395	268.194	268, 215, 185, 136, 133, 109, 93, 82, 54	C ₁₀ H ₁₂ N ₄ O ₅	Inosine

460

461

462

463

464 **Supplementary 1**

465 The antimicrobial effect of *Holothuria atra* on *P. aeruginosa* PA14 as determined by Minimum
466 Inhibitory Concentration (MIC) test*.

Samples	Concentration (µg/mL)				
	25	50	100	500	1000
<i>Holothuria atra</i> -methanol	-	-	-	-	-
<i>Holothuria atra</i> -fraction F3	-	-	-	-	-
Streptomycin**			+		

467 * + denotes inhibition; – denotes no inhibition of PA14 growth

468 ** 100 ug/ml streptomycin was used as control

Figure 1. Improved survival of *P. aeruginosa* PA14-infected *C. elegans* at 48 hours after treatment with *Holothuria atra* extracts (200 µg/mL). The methanol extract showed the highest percentage of survival. Data were analyzed using Student's *t*-test where ** denotes significance at $p<0.01$ when compared to 0.5% DMSO treatment. Curcumin was used as positive control.

Figure 2. Hourly growth rate of *P. aeruginosa* PA14 in the presence of 200 µg/mL *Holothuria atra* methanolic extract. Growth was comparable to 0.5% DMSO treatment while streptomycin (100 µg/mL) reduced bacterial proliferation.

Figure 3. Pharyngeal pumping rate of *C. elegans* fed *E. coli* OP-50, *Pseudomonas aeruginosa* PA14 untreated, PA14 treated with 0.5% DMSO and PA14 treated with *Holothuria atra* methanol extract at 200 µg/mL at 0, 12 or 24hr after treatment. Values were compared to 0.5% DMSO treatment for each respective hr after treatment using Student's *t*-test at $p<0.05$ and $p<0.01$, respectively.

A

B)

C)

Figure 4. A) Survival of *P. aeruginosa* PA14-infected *C. elegans* at 48 hours after treatment with *Holothuria atra* fractions F1-F9. The F3 fraction showed the highest percentage of survival. Data were analyzed using Student's *t*-test where * and ** denotes significance at $p<0.05$ and $p<0.01$ respectively when compared to 0.5% DMSO treatment. Curcumin, used as positive control, also prolonged worm survival significantly. B) Dose dependent response of *P. aeruginosa* PA14-infected *C. elegans* at 48 hours after treatment with *Holothuria atra* fraction F3. Data were analyzed using Student's *t*-test where * at $p<0.05$ when compared to 0.5% DMSO treatment. Curcumin, as positive control, also prolonged worm survival significantly. C) Hourly growth rate of *P. aeruginosa* PA14 in the presence of 200 $\mu\text{g/mL}$ *Holothuria atra* fraction F3. Growth was comparable to 0.5% DMSO treatment while streptomycin (100 $\mu\text{g/mL}$) reduced bacterial proliferation.

A)

B)

Figure 5 Effect of *Holothuria atra* F3 fraction on production of *P. aeruginosa* PA14 virulence factors (A) Reduced production elastase, protease and biofilm at 24 hr after exposure to F3 (B) Reduced pyocyanin production at 6 and 12 hr after exposure. Data were analyzed using Student's *t*-test where * and ** denotes significance at $p<0.05$ and $p<0.01$ respectively when compared to 0.5% DMSO treatment.

Figure 6. A) *Holothuria atra* restore *lys-7* expression in *P. aeruginosa* PA14 infected *C. elegans*. Representative fluorescence micrographs (60x magnification) of transgenic *lys-7::GFP* worms fed with *E. coli* OP50 (a), infected with *P. aeruginosa* PA14 and treatment with 0.5% DMSO (b), infected with *P. aeruginosa* PA14 and treatment with F3 (c). Images were captured at 12 hr after treatment. (B) qPCR of *C. elegans lys-7* in PA14 infected worms treated with 0.5% DMSO, *H. atra* F3 fraction or curcumin at 12 or 24 hrs. Data were analyzed using Student's *t*-test where * and ** denotes significance at $p<0.05$ and $p<0.01$ respectively when normalized to 0.5% DMSO treatment.